A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 22, 2017

Primary Completion Date

October 15, 2018

Study Completion Date

October 30, 2018

Conditions

Cancer of Prostate

Interventions

DRUG

LY01005

One gluteal IM injection

DRUG

Zoladex

One Subcutaneous injection in the abdominal wall

Trial Locations (5)

Clinical Research Center of Flordia, Pompano Beach

South Florida Medical Research, Aventura

Florida Urology Partners, Tampa

Pinnacle Research LLC, Anniston

Urology, San Antonio, San Antonio

All Listed Sponsors

lead

Luye Pharma Group Ltd.

INDUSTRY

NCT03450109 - A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter